Brief: Exelixis And Ipsen Announce Positive Results From Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib In Combination With Atezolizumab
21/08/2023 06:19
Aug 21 (Reuters) - Ipsen SA IPN.PA :
* EXELIXIS AND IPSEN ANNOUNCE POSITIVE RESULTS FROM PHASE 3
CONTACT-02 PIVOTAL TRIAL EVALUATING CABOZANTINIB IN COMBINATION
WITH ATEZOLIZUMAB IN METASTATIC CASTRATION-RESISTANT PROSTATE
CANCER
* CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB DEMONSTRATED
A
STATISTICALLY SIGNIFICANT REDUCTION IN RISK OF DISEASE
PROGRESSION OR DEATH COMPARED WITH A SECOND NOVEL HORMONAL
THERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT
PROSTATE CANCER
* A TREND TOWARD IMPROVEMENT IN OVERALL SURVIVAL WAS
OBSERVED AT
FIRST INTERIM ANALYSIS
* FINDINGS WILL BE PRESENTED AT AN UPCOMING MEDICAL MEETING
AND
DISCUSSED WITH HEALTH AUTHORITIES GLOBALLY
Source text for Eikon: ID:nGNE5gV5rL
Further company coverage: IPN.PA ; EXEL.O
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))